TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

This study is testing a combination of chemotherapy drugs (called the TIP regimen) plus an immunotherapy drug (triplizumab) given before surgery for locally advanced penile cancer. The goal is to shrink the tumor before surgery, which may allow for better surgical outcomes. **You may be eligible if...** - You have been diagnosed with locally advanced penile cancer confirmed by biopsy - Your cancer is at an advanced local stage (T4 or N3, or both) - You have not had chemotherapy before, or your cancer relapsed more than 12 months after your last treatment - You have at least one measurable tumor visible on scans - Your general health is good (ECOG score 0–2) - Your blood counts and organ function are within acceptable ranges - Your expected survival is at least 12 months **You may NOT be eligible if...** - You have significant nerve damage affecting your daily function - You received an experimental drug in the 4 weeks before enrolling - You have another active cancer (with some exceptions for fully treated, low-risk cancers) Talk to your doctor to see if this trial is right for you.